FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2793189189> ?p ?o ?g. }

• W2793189189 abstract "Exchange transfusion and phototherapy have traditionally been used to treat jaundice and avoid the associated neurological complications. Because of the risks and burdens of exchange transfusion, intravenous immunoglobulin (IVIg) has been suggested as an alternative therapy for alloimmune hemolytic disease of the newborn (HDN) to reduce the need for exchange transfusion.To assess the effect and complications of IVIg in newborn infants with alloimmune HDN on the need for and number of exchange transfusions.We performed electronic searches of CENTRAL, PubMed, Embase (Ovid), Web of Science, CINAHL (EBSCOhost), Academic Search Premier, and the trial registers ClinicalTrials.gov and controlled-trials.com in May 2017. We also searched reference lists of included and excluded trials and relevant reviews for further relevant studies.We considered all randomized and quasi-randomized controlled trials of IVIg in the treatment of alloimmune HDN. Trials must have used predefined criteria for the use of IVIg and exchange transfusion therapy to be included.We used the standard methods of Cochrane and its Neonatal Review Group. We assessed studies for inclusion and two review authors independently assessed quality and extracted data. We discussed any differences of opinion to reach consensus. We contacted investigators for additional or missing information. We calculated risk ratio (RR), risk difference (RD) and number needed to treat for an additional beneficial outcome (NNTB) for categorical outcomes. We calculated mean difference (MD) for continuous variables. We used GRADE criteria to assess the risk of bias for major outcomes and to summarize the level of evidence.Nine studies with 658 infants fulfilled the inclusion criteria. Term and preterm infants with Rh or ABO (or both) incompatibility were included. The use of exchange transfusion decreased significantly in the immunoglobulin treated group (typical RR 0.35, 95% CI 0.25 to 0.49; typical RD -0.22, 95% CI -0.27 to -0.16; NNTB 5). The mean number of exchange transfusions per infant was also significantly lower in the immunoglobulin treated group (MD -0.34, 95% CI -0.50 to -0.17). However, sensitivity analysis by risk of bias showed that in the only two studies in which the treatment was masked by use of a placebo and outcome assessment was blinded, the results differed; there was no difference in the need for exchange transfusions (RR 0.98, 95% CI 0.48 to 1.98) or number of exchange transfusions (MD -0.04, 95% CI -0.18 to 0.10). Two studies assessed long-term outcomes and found no cases of kernicterus, deafness or cerebral palsy.Although overall results show a significant reduction in the need for exchange transfusion in infants treated with IVIg, the applicability of the results is limited because of low to very low quality of evidence. Furthermore, the two studies at lowest risk of bias show no benefit of IVIg in reducing the need for and number of exchange transfusions. Based on these results, we have insufficient confidence in the effect estimate for benefit of IVIg to make even a weak recommendation for the use of IVIg for the treatment of alloimmune HDN. Further studies are needed before the use of IVIg for the treatment of alloimmune HDN can be recommended, and should include blinding of the intervention by use of a placebo as well as sufficient sample size to assess the potential for serious adverse effects." @default.
• W2793189189 created "2018-03-29" @default.
• W2793189189 creator A5030808557 @default.
• W2793189189 creator A5037091735 @default.
• W2793189189 creator A5046085286 @default.
• W2793189189 creator A5084227679 @default.
• W2793189189 creator A5085054771 @default.
• W2793189189 date "2018-03-18" @default.
• W2793189189 modified "2023-09-30" @default.
• W2793189189 title "Immunoglobulin for alloimmune hemolytic disease in neonates" @default.
• W2793189189 cites W1486737843 @default.
• W2793189189 cites W1488110714 @default.
• W2793189189 cites W1507087026 @default.
• W2793189189 cites W1523697063 @default.
• W2793189189 cites W1526715483 @default.
• W2793189189 cites W1562271219 @default.
• W2793189189 cites W1579486423 @default.
• W2793189189 cites W1636522100 @default.
• W2793189189 cites W1874218143 @default.
• W2793189189 cites W192507899 @default.
• W2793189189 cites W1965736833 @default.
• W2793189189 cites W1965801028 @default.
• W2793189189 cites W1984229257 @default.
• W2793189189 cites W1991890821 @default.
• W2793189189 cites W1993299402 @default.
• W2793189189 cites W1994779241 @default.
• W2793189189 cites W2003131947 @default.
• W2793189189 cites W2009441748 @default.
• W2793189189 cites W2011663265 @default.
• W2793189189 cites W2030917541 @default.
• W2793189189 cites W2032038898 @default.
• W2793189189 cites W2055690842 @default.
• W2793189189 cites W2063063994 @default.
• W2793189189 cites W2070223939 @default.
• W2793189189 cites W2074186439 @default.
• W2793189189 cites W2075479460 @default.
• W2793189189 cites W2087028443 @default.
• W2793189189 cites W2109374347 @default.
• W2793189189 cites W2109966521 @default.
• W2793189189 cites W2112317428 @default.
• W2793189189 cites W2117880641 @default.
• W2793189189 cites W2118604374 @default.
• W2793189189 cites W2122227093 @default.
• W2793189189 cites W2122228073 @default.
• W2793189189 cites W2126487248 @default.
• W2793189189 cites W2143804546 @default.
• W2793189189 cites W2145704825 @default.
• W2793189189 cites W2150441222 @default.
• W2793189189 cites W2157730045 @default.
• W2793189189 cites W2158656750 @default.
• W2793189189 cites W2160167526 @default.
• W2793189189 cites W2161776820 @default.
• W2793189189 cites W2161842679 @default.
• W2793189189 cites W2171469214 @default.
• W2793189189 cites W2285466744 @default.
• W2793189189 cites W2325659923 @default.
• W2793189189 cites W2349278249 @default.
• W2793189189 cites W2399597476 @default.
• W2793189189 cites W2409761677 @default.
• W2793189189 cites W2539277522 @default.
• W2793189189 cites W2719226347 @default.
• W2793189189 cites W2793189189 @default.
• W2793189189 cites W2982262074 @default.
• W2793189189 cites W4242853356 @default.
• W2793189189 cites W4244527287 @default.
• W2793189189 cites W4246636883 @default.
• W2793189189 cites W4253580602 @default.
• W2793189189 cites W86373604 @default.
• W2793189189 doi "https://doi.org/10.1002/14651858.cd003313.pub2" @default.
• W2793189189 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6494160" @default.
• W2793189189 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29551014" @default.
• W2793189189 hasPublicationYear "2018" @default.
• W2793189189 type Work @default.
• W2793189189 sameAs 2793189189 @default.
• W2793189189 citedByCount "27" @default.
• W2793189189 countsByYear W27931891892018 @default.
• W2793189189 countsByYear W27931891892020 @default.
• W2793189189 countsByYear W27931891892021 @default.
• W2793189189 countsByYear W27931891892022 @default.
• W2793189189 countsByYear W27931891892023 @default.
• W2793189189 crossrefType "journal-article" @default.
• W2793189189 hasAuthorship W2793189189A5030808557 @default.
• W2793189189 hasAuthorship W2793189189A5037091735 @default.
• W2793189189 hasAuthorship W2793189189A5046085286 @default.
• W2793189189 hasAuthorship W2793189189A5084227679 @default.
• W2793189189 hasAuthorship W2793189189A5085054771 @default.
• W2793189189 hasBestOaLocation W27931891892 @default.
• W2793189189 hasConcept C118552586 @default.
• W2793189189 hasConcept C120195587 @default.
• W2793189189 hasConcept C126322002 @default.
• W2793189189 hasConcept C168563851 @default.
• W2793189189 hasConcept C172680121 @default.
• W2793189189 hasConcept C177713679 @default.
• W2793189189 hasConcept C187212893 @default.
• W2793189189 hasConcept C27415008 @default.
• W2793189189 hasConcept C2776478404 @default.
• W2793189189 hasConcept C2778444020 @default.
• W2793189189 hasConcept C2779042277 @default.
• W2793189189 hasConcept C2779234561 @default.
• W2793189189 hasConcept C2780014101 @default.

• next